Abstract
Voriconazole is effective for prophylaxis and therapy of invasive fungal infections (IFI). It is metabolized by the CYP450 system 2C19, 2C9 and 3A4 isosenzymes. We have reported that significant interpatient variability exists in plasma voriconazole concentrations after allogeneic HSCT and that about 15% of patients have no detectable voriconazole in the plasma despite adequate dose (Trifilio et al. Cancer 2007;109:1532–1535). Low plasma levels have also been associated with decreased survival in patients with aspergillosis and increased breaktrough Candida glabrata infections (Trifilio et al.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
